Qiagen (NYSE:QGEN) was downgraded by equities research analysts at TheStreet from a “b” rating to a “c+” rating in a research note issued to investors on Tuesday, TheStreetRatingsTable reports.
A number of other brokerages have also weighed in on QGEN. Berenberg Bank upgraded Qiagen from a “hold” rating to a “buy” rating in a research report on Monday, August 17th. Kepler Capital Markets upgraded Qiagen from a “hold” rating to a “buy” rating and set a $59.32 price objective on the stock in a research report on Monday, September 28th. Citigroup upgraded Qiagen from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $48.00 to $62.00 in a research report on Monday, August 24th. Bank of America upgraded Qiagen from a “neutral” rating to a “buy” rating and set a $59.00 price objective on the stock in a research report on Tuesday, October 6th. Finally, DZ Bank reiterated a “neutral” rating on shares of Qiagen in a research report on Tuesday, September 15th. Nine research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $50.72.
QGEN opened at $48.69 on Tuesday. The stock’s 50 day simple moving average is $51.48 and its 200 day simple moving average is $46.67. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.71 and a quick ratio of 1.50. Qiagen has a 1 year low of $28.70 and a 1 year high of $55.27. The firm has a market cap of $11.09 billion, a price-to-earnings ratio of 1,623.00, a PEG ratio of 1.46 and a beta of 0.31.
Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.02. Qiagen had a return on equity of 15.85% and a net margin of 0.86%. As a group, sell-side analysts anticipate that Qiagen will post 2.08 EPS for the current year.
Large investors have recently made changes to their positions in the business. NuWave Investment Management LLC purchased a new position in Qiagen during the second quarter valued at $36,000. Mitsubishi UFJ Trust & Banking Corp purchased a new position in Qiagen during the second quarter valued at $73,000. CSat Investment Advisory L.P. raised its stake in shares of Qiagen by 377.1% in the second quarter. CSat Investment Advisory L.P. now owns 3,674 shares of the company’s stock worth $157,000 after purchasing an additional 2,904 shares during the last quarter. World Asset Management Inc purchased a new position in shares of Qiagen in the third quarter worth $212,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Qiagen in the third quarter worth $214,000. Institutional investors and hedge funds own 61.81% of the company’s stock.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Featured Story: Is it Safe to Invest in Commodities?
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.